Cardiol Therapeutics (TSE:CRDL) Trading Up 0.8%

Cardiol Therapeutics Inc. (TSE:CRDL)’s stock price traded up 0.8% on Wednesday . The company traded as high as C$2.65 and last traded at C$2.60. 87,328 shares changed hands during mid-day trading, a decline of 39% from the average session volume of 142,417 shares. The stock had previously closed at C$2.58.

Cardiol Therapeutics Stock Performance

The firm has a market capitalization of C$174.00 million, a PE ratio of -5.91 and a beta of 0.70. The company has a debt-to-equity ratio of 1.07, a current ratio of 2.39 and a quick ratio of 6.84. The company’s fifty day simple moving average is C$2.78 and its 200 day simple moving average is C$2.72.

Insider Buying and Selling at Cardiol Therapeutics

In related news, Director David Elsley purchased 50,000 shares of the firm’s stock in a transaction dated Monday, June 24th. The shares were purchased at an average cost of C$2.77 per share, for a total transaction of C$138,490.00. Insiders own 4.57% of the company’s stock.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.